Drug Trial Radar · NCT01638000
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,887
Actual
Start
Jun 12, 2012
Primary completion
Apr 24, 2013
Study completion Apr 24, 2013
Sponsor
- Lead sponsor
- Astellas Pharma Europe Ltd.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jul 11, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of efficacy.
Conditions
- Urologic Diseases
- Urinary Bladder, Overactive
- Urinary Bladder Diseases
Interventions
MirabegronDrug
oral tablet
Solifenacin succinateDrug
oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 HoursTime frame: Baseline and final visit (up to Week 12)
Locations
217 sites in 33 countries. Site status is shown where the registry gives one.
Site: 37406
Yerevan, Armenia
Site: 37404
Yerevan, Armenia
Site: 37403
Yerevan, Armenia
Site: 37401
Yerevan, Armenia
Site: 37402
Yerevan, Armenia
Site: 43006
Baden, Austria
Site: 43014
Graz, Austria
Site: 43015
Innsbruck, Austria
Site: 43013
Linz, Austria
Site: 43005
Oberwart, Austria
Site: 43011
Vienna, Austria
Site: 43002
Vienna, Austria
Site: 43003
Wels, Austria
Site: 37502
Minsk, Belarus
Site: 37501
Minsk, Belarus
Site: 37504
Vitebsk, Belarus
Site: 32006
Brussels, Belgium
Site: 32008
Deurne, Belgium
Site: 32001
Edegem, Belgium
Site: 32004
Ghent, Belgium
Site: 32007
Leuven, Belgium
Site: 32005
Liège, Belgium
Site: 35902
Burgas, Bulgaria
Site: 35909
Haskovo, Bulgaria
Site: 35901
Lovech, Bulgaria
Site: 35905
Plovdiv, Bulgaria
Site: 35906
Sofia, Bulgaria
Site: 35908
Sofia, Bulgaria
Site: 35903
Sofia, Bulgaria
Site: 10010
Abbotsford British Columbia, Canada
Site: 10011
Barrie, Canada
Site: 10001
Bathurst, Canada
Site: 10003
Brampton, Canada
Site: 10005
Brantford, Canada
Site: 10007
Kingston, Canada
Site: 10002
Montreal, Canada
Site: 10009
Sherbrooke, Canada
Site: 10004
Toronto, Canada
Site: 10008
Victoria, Canada
Site: 42004
Bohumín, Czechia
Showing 40 of 217 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.